Orosoluble and/or effervescent compositions containing at least a salt of s-adenosyl methionine (same)
AssigneeGraal Srl
InventorAlessandro Seneci
Life of this patent
Estimating the term…
Abstract
The present invention refers to pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent compositions for oral use containing at least a salt of S-adenosyl methionine (SAMe), combined with physiologically acceptable excipients and optionally additional active ingredients. In particular the invention refers to compositions with high palatability formulated in tablet, capsule or granules. The present invention also refers to the use of at least a salt of SAMe combined with physiologically acceptable excipients and optionally further active ingredients for treating, human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases.
Claims19
Pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent composition containing at least a salt of S-adenosyl methionine combined with physiologically acceptable excipients wherein said physiologically acceptable excipients comprise light magnesium oxide.
Composition according to claim in form of tablet, capsule or granules.
Method for obtaining the plasma peak of the SAMe ion within a period of time comprised between 1 and 2 hours characterized by administering a Pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent composition containing at least a salt of S-adenosyl methionine combined with physiologically acceptable excipients wherein said physiologically acceptable excipients comprise light magnesium oxide.
Method for determining a plasma concentration of the SAMe ion higher than 40-50% with respect to the base value within a period of time comprised between 1 and 2 hours characterized by administering a Pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent composition containing at least a salt of S-adenosyl methionine combined with physiologically acceptable excipients wherein said physiologically acceptable excipients comprise light magnesium oxide.
Dependencies are inferred from the claim text.